The Federal 340B Drug Discount Program. Compliance and Lessons Learned. Jason Reddish September 24, 2014
|
|
- Stewart Carpenter
- 5 years ago
- Views:
Transcription
1 The Federal 340B Drug Discount Program Compliance and Lessons Learned Jason Reddish September 24, 2014
2 About Me Jason Reddish Attorney Powers Pyles Sutter & Verville PC 1501 M Street NW, 7 th Floor Washington, DC (202) jason.reddish@ppsv.com
3 Disclaimer This presentation is for informational purposes only and does not create an attorney/client relationship between the presenter and any other person or party.
4 Outline Overview of the 340B Program Eligibility and Registration Compliance Major Program Requirements Diversion, Duplicate Discounts, Auditable Records Contract Pharmacies Audits and Lessons Learned The Mega-Reg, Litigation, and Political Issues
5 Overview of the 340B Program Congress created the 340B program in 1992 to provide certain categories of safety net providers ( covered entities ) relief from high drug prices Stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services Statute updated in Affordable Care Act to add rural hospitals, expand program oversight
6 How Does 340B Work? Drug manufacturers must agree to offer discounted drugs to covered entities in order for Medicare and Medicaid to cover their drugs Manufacturers can charge no more than the ceiling price Savings average 25-50% Average Manufacturer Price (AMP) minus Medicaid Unit Rebate Amount (URA) specific to each National Drug Code (NDC) Covered entities provide 340B drugs to their patients and use savings to increase patient services
7 Manufacturers must offer discounts for covered outpatient drugs Prescription Drugs OTC Drugs When Prescribed Biologics Insulin Separately Reimbursable Clinic/Physician-Administered Drugs Other drugs are not discounted Vaccines Drugs that are not directly reimbursed Drugs for which the FDA does not require a NDC Which Drugs?
8 Who Oversees 340B? The Office of Pharmacy Affairs (OPA) within HRSA OPA is part of the Healthcare Systems Bureau, a sibling of the Bureau of Primary Health Care and HIV/AIDS Bureau Commander Krista Pedley has led OPA since 2010
9 What Is Apexus? Apexus serves two roles for OPA Prime Vendor Program Technical Assistance Contractor 340B University Apexus Answers
10 Provider Eligibility Who Can Participate? Certain Public or Non-Profit Hospitals Disproportionate Share Hospitals Critical Access Hospitals Rural Referral Centers Sole Community Hospitals Free-Standing Cancer Hospitals Free-Standing Children s Hospitals Certain Federal Grantees Federally-qualified health centers (FQHCs) and look-alikes (FQHC-LAs) Clinics funded under the Ryan White CARE Act AIDS Drug Assistance Programs (ADAPs) Hemophilia Treatment Centers Family Planning/STD Urban Indian/Native Hawaiian Black Lung/Tuberculosis
11 FQHCs What Sites Are Eligible? FQHCs deliver care in many ways and often in multiple locations All sites that use 340B drugs must be registered OPA will only register sites that are authorized in the grant Satellite locations? Temporary or part-time clinics? Shared spaces? Mobile units?
12 Registration OPA only permits new entities and new entity sites to be registered on a quarterly basis: Jan. 1 to 15 to begin Apr. 1 Apr. 1 to 15 to begin July 1 July 1 to 15 to begin Oct. 1 Oct. 1 to 15 to begin Jan. 1 Must provide eligibility information (grant number), Authorizing Official, Primary Contact
13 OPA 340B Database opanet.hrsa.gov/opa/ OPA maintains a database of covered entities, contract pharmacies, and manufacturers Covered entities responsible for ensuring that all database information is accurate Altered through online change request process in most cases not tied to registration windows If information is inaccurate, critical communications might be missed
14 Must recertify eligibility annually FQHCs are slated to recertify in February 2015 Ryan White clinics likely will recertify in winter 2014/2015 Failure to recertify = removal from program Dates subject to change Recertification
15 340B Program Requirements FQHCs and Grantees must comply with: Diversion Prohibition Duplicate Discount Prohibition Auditable Recordkeeping Other requirements are implicated by the 340B program, but 340B audits do not examine them E.g., anti-kickback statute, False Claims Act, patient inducement prohibition, Prescription Drug Marketing Act
16 Diversion Prohibition [A] covered entity shall not resell or otherwise transfer [a 340B] drug to a person who is not a patient of the entity. Sec. 340B(a)(5)(B) of the Public Health Service Act. Violation of this provision is diversion Most clear-cut diversion would be reselling 340B drugs on the black market
17 Who Is a Patient? Most often, diversion occurs because 340B drugs are provided to someone other than a patient of the covered entity. HRSA has published guidance on who qualifies as a patient of a 340B covered entity.
18 1996 Patient Definition Under the 1996 Patient Definition - 61 Fed. Reg. 55,156 (Oct. 24, 1996) an individual is a patient if: 1. The covered entity has established a relationship with the individual, such that the covered entity maintains records of the individual s health care. This is called the record maintenance test
19 1996 Patient Definition 2. The individual receives health care services from a health care professional who is either employed by the covered entity or provides health care under contractual or other arrangements (e.g., referral for consultation) such that responsibility for the care provided remains with the covered entity. This is called the professional care test.
20 1996 Patient Definition 3. The individual receives a health care service or range of services from the covered entity which is consistent with the service or range of services for which grant funding or federally-qualified health center look-alike status has been provided to the entity. This is the scope of grant test. Two caveats not a patient if only health care service is dispensing of drugs for selfadministration; individuals registered with ADAPs are patients of the ADAP.
21 Record Maintenance Test What is a record? HRSA declined to define the necessary record as a medical record, though a medical record certainly qualifies Record likely should reflect the patient s drug treatment, any care provided by the covered entity, and any referrals Some have argued that nontraditional records (case management, billing records) could meet this test in some circumstances
22 Professional Care Test Who is a health care professional? Some say it must be a prescriber Others rely on nurses and even social workers What is a health care service? Open to interpretation What are other arrangements? Guidance gives example of referral for consultation but implies that other types of relationships could qualify
23 Scope of Grant Test What health care service or range of services are consistent with the service or range of services for which grant funding has been provided? For FQHCs with general primary care responsibilities, could be broad If the grant is limited to specific services, patient scope might be limited Likely limited to treatment that occurs at locations described in the grant
24 Other Considerations In January 2001, HRSA Deputy Administrator Thomas Morford issued a letter describing circumstances in which care outside a covered entity could still qualify for 340B Letter was specific to hospitals, but current FAQ 1891 from Apexus states: Q: If we refer a patient to an outside clinic, can we fill their prescriptions from our 340B clinic? A: A covered entity may send a patient to an outside clinic not registered with 340B and consider that patient 340B eligible only if the 340B patient receives health care from a health care professional who is either employed by the covered entity or provides health care under contractual or other arrangements (e.g., referral for consultation) such that responsibility for the care provided remains with the covered entity (61 Fed. Reg (October 24, 1996)). If the covered entity can document that it retained responsibility for the health care services provided to the patient, then that individual may be eligible to receive 340B drugs from the covered entity. What does it mean to retain responsibility?
25 Inventory Management Physical Inventory 340B drugs are kept physically separate from any non-340b drugs Eligible patients receive 340B drugs. Ineligible patients receive other stock. Best used in pharmacies that are limited to patients
26 Inventory Management Virtual Inventory Starting inventory is neutral neither 340B or non- 340B Inventory dispensed to eligible patients is tracked, and re-ordered through 340B accounts Inventory dispensed to ineligible patients is tracked, and re-ordered through regular channels Diversion occurs when 340B drugs go to ineligible patients (physical inventory) or when drugs dispensed to ineligible patients are replenished with 340B drugs (virtual inventory)
27 Duplicate Discounts A covered entity shall not request payment under [Medicaid] with respect to a drug that is [bought through 340B] if the drug is subject to the payment of a rebate to the state. Sec. 340B(a)(5)(A) of the Public Health Service Act Covered outpatient drugs are rebate-eligible, so covered entities must ensure that manufacturers are not subjected to both a rebate and the 340B discount a duplicate discount.
28 Medicaid Exclusion File When a covered entity registers, HRSA asks whether it will bill Medicaid for 340B drugs If yes, the covered entity is added to the Medicaid Exclusion File so states know not to claim a rebate for drugs billed by the covered entity If no, the covered entity must not bill Medicaid for 340B drugs
29 Alabama Requirement Alabama Administrative Code Sec. 560-X-1-.30(1)(b): When an eligible 340B entity, other than a disproportionate share hospital, a children s hospital excluded from the Medicare prospective payment system, a free-standing cancer hospital exempt from the Medicare prospective payment system, sole community hospital, rural referral center, or critical access hospital, submits a bill to the Medicaid Agency for a drug purchased by or on behalf of a Medicaid recipient, the amount billed shall not exceed the entity's actual acquisition cost for the drug, as charged by the manufacturer at a price consistent with the Veterans Health Care Act of 1992, plus the dispensing fee established by the Medicaid Agency.
30 What About Managed Care? Drugs covered by Medicaid managed care are eligible for rebates Alabama will be moving to Medicaid managed care using Regional Care Organizations (RCOs) The duplicate discount prohibition describes billing Medicaid, and the Alabama regulation describes billing the Medicaid Agency RCOs will be private payers, so covered entities will not be billing Medicaid directly If billing Medicaid in neighboring states, must be wary of managed care-specific 340B requirements
31 What About ADAPs? AIDS Drug Assistance Programs can participate in 340B in one of two ways: By contracting with pharmacies to dispense ADAPpurchased drug inventory By obtaining a rebate equal to the 340B discount on any drugs it covers What if ADAP covers drug that was purchased by covered entity? Duplicate discount risk. Not addressed in statute, but HRSA says ADAPs must avoid rebates on 340B drugs. Some ADAPs restrict covered entities or reduce reimbursement.
32 Auditable Records A covered entity shall permit the Secretary and the manufacturer of a covered outpatient drug that is subject to an agreement under this subsection with the entity (acting in accordance with procedures established by the Secretary relating to the number, duration, and scope of audits) to audit at the Secretary s or the manufacturer s expense the records of the entity that directly pertain to the entity s compliance with the diversion and duplicate discount requirements. Sec. 340B(a)(5)(C) of the Public Health Service Act.
33 Auditable Records HRSA has taken the position that maintenance of auditable records is an eligibility requirement, and has threatened to terminate entities that fail to maintain adequate records
34 Self-Disclosure As part of annual recertification, the Authorizing Official must attest that the covered entity will inform OPA of any material breaches of program requirements
35 Self-Disclosure Upon a selfdisclosure of noncompliance, OPA will generally require the covered entity to notify affected manufacturers and, if necessary, offer repayment
36 Contract Pharmacies A contract pharmacy is a pharmacy that a covered entity uses as its agent for the ordering, dispensing, and billing of 340B drugs
37 Contract Pharmacy Growth In 2010, HRSA expanded contract pharmacy guidance to permit multiple pharmacies
38 Contract Pharmacy Basics Voluntary, but essentially required for participation if covered entity does not dispense or administer drugs on site HRSA requires a written contract meeting certain essential compliance elements Covered entity completely and 100% responsible for compliance of contract pharmacy
39 Creating a Contract Pharmacy Arrangement 1) Identify a partner 2) Negotiate and execute a contract 3) Register the arrangement with OPA during one of the four quarterly enrollment periods January 1 to 15; April 1 to 15; July 1 to 15; October 1 to 15 4) Wait until the registration becomes effective and appears in the OPA database The first day of the quarter following the registration period, if approved. E.g., April 1 if registered during January 1 to 15 window 5) Go live Process requires a minimum of 2.5 months from execution of contract to commencement.
40 HRSA published contract pharmacy guidelines in the Federal Register on March 5, Fed. Reg. 10,272 The Contract HRSA Guidelines The contract establishing the contract pharmacy arrangement must address 13 essential compliance elements.
41 Essential Compliance Elements The agreement must address the following elements: 1) Covered entity (CE) purchases each drug, maintains title to each drug, and assumes responsibility for establishing its price; Element is required but somewhat conceptually strained in a virtual inventory model. 2) A ship to, bill to procedure will be used such that the CE purchases the drug, but it is shipped to the pharmacy (Rx); 3) How comprehensive pharmacy services will be provided, and how they will be divided between CE and Rx;
42 Essential Compliance Elements (cont.) 4) CE will inform patients of their freedom to choose a pharmacy provider; 5) Rx may provide other services to CE or patients (though 340B drugs are restricted to patients); 6) Rx and CE will adhere to all federal, state, and local laws and requirements; 7) Rx will provide CE with reports consistent with customary business practices; 8) Rx and CE will establish and maintain a tracking system suitable to prevent diversion to nonpatients;
43 Essential Compliance Elements (cont.) 9) Rx and CE will develop a system to develop patient eligibility; 10) Neither party will use 340B drugs for Medicaid prescriptions unless CE, Rx, and state Medicaid agency have a way to prevent duplicate discounts; 11) CE and Rx will identify whatever information is needed for CE to meet its compliance obligations; 12) CE and Rx understand that they may be audited; and
44 Essential Compliance Elements (cont.) 13) CE and/or Rx will provide a copy of the contract to OPA upon request Compliance with 340B program rules is ALWAYS the responsibility of the CE alone.
45 Essential Compliance Elements (cont.) An auditor will want to see that the essential compliance elements have all been addressed If your contract would allow it, try to repeat the elements verbatim Otherwise, consider including a crosswalk that shows where each essential compliance element is addressed in your agreement
46 Other Considerations Compliance with 340B program rules is ALWAYS the responsibility of the CE alone No matter what Even if someone else makes a mistake Even if the pharmacy or an administrator breaches a contractual obligation Indemnification is critical
47 Other Considerations (cont.) Many topics that are not essential compliance elements should also be addressed: Indemnification Audits Annual independent audits Cooperation with HRSA/Manufacturer audits Shipment verification Periodic inventory reconciliation What happens if over-replenishment (more 340B inventory than expected) or under-replenishment (less 340B inventory than expected) has occurred? What happens if drugs are slow-moving, discontinued, out-of-stock, or otherwise unavailable for replenishment? Record retention
48 Other Considerations (cont.) OPA Registration Third-party billing and reimbursement Compensation of Rx/Administrator Boilerplate Consequential damages (can you be made whole?) Term and termination Confidentiality and privacy Dispute resolution Wind-down Insurance Intellectual property
49 Audits and Lessons Learned HRSA and drug manufacturers have always had the authority to audit covered entities, but no audits until (fiscal year Oct. 1, 2011 to Sept. 30, 2012) 51 audits covering 410 locations (child sites) and 860 contract pharmacy sites audits covering 718 locations and 1,937 contract pharmacy sites audits covering 1,470 locations and 4,000+ contract pharmacies 2015 No more sequester and increased funding, HRSA hoping to double audits
50 Who Gets Audited? HRSA conducts risk-based and targeted audits Risk factors include purchase volume, increased complexity of administration, number of child sites, and number of contract pharmacies Targeted audits respond to allegations Manufacturers must show probable cause of a violation and obtain approval from HRSA Very few manufacturer audits to date (six or seven) Manufacturers report that audits are expensive and HRSA provides little assistance
51 Who Gets Audited? 10 of 51 in 2012 were community health centers 2 of the 27 results released thus far for 2013 are community health centers The majority are hospitals
52 Anatomy of an Audit 1. Notice from HRSA Brief letter informing covered entity that it has been selected for an audit Audit includes all child sites and contract pharmacies 2. Coordination Call HRSA reaches out to coordinate the date and details of the audit
53 Anatomy of an Audit 3. Data Request HRSA sends the covered entity a list of data that the covered entity must produce to the auditor, including items such as: all 340B prescriptions and related information over a sixmonth time frame starting and ending inventory balances for the same period; a schedule of 340B purchases a list of the covered entity s participating locations a list of the covered entity s physicians eligible to dispense and write 340B prescriptions 340B policies and procedures contact information
54 Anatomy of an Audit 4. The Audit Typically takes place over one to two days Involves testing certain transactions for compliance with diversion and duplicate discount prohibitions Will include a review of eligibility documentation (grant) Will include a review of policies and procedures No longer concludes with an exit conference (as of October 1)
55 After the Audit Until very recently, HRSA issued a preliminary audit report and gave the covered entity an opportunity to respond Now, HRSA goes directly to a final audit report Concerns regarding whether this satisfies notice and hearing requirement in statute and constitutional due process.
56 Final Audit Report If the report contains no adverse findings, the audit is complete If the audit contains adverse findings, the covered entity must either: Submit a notice of disagreement within 30 days; or Submit a corrective action plan and letter to manufacturers within 60 days
57 Corrective Action Plan The primary sanction available to HRSA is to require repayment of the 340B discount to affected manufacturers How far back? How do you identify all instances? What if you cannot identify all instances? What if you cannot afford repayment? Interest can be assessed if the violation was knowing and intentional; termination if also systematic and egregious
58 Notice of Disagreement The Notice of Disagreement is the covered entity s one chance to set the record straight HRSA does not grant in-person hearings on the evidence A Notice of Disagreement typically raises factual and legal arguments in opposition to the adverse findings The person was a patient ; No duplicate discounts occurred ; We have not been afforded adequate due process ; HRSA does not have the authority to enforce the standard ; etc.
59 The FINAL Final Audit Report HRSA might or might not alter its findings before issuing a final Final Audit Report The covered entity s only recourse is to file suit
60 What Did We Learn?
61 Lessons Learned HRSA s audit protocol is not published, and has evolved since audits began Many different data requests Many different audit experiences HRSA auditors much more sophisticated than in early audits Government Auditing Standards are not used audits are informal
62 Lessons Learned The auditor conveys information to HRSA, but does not draft the Final Audit Report An auditor might give the impression that everything is in perfect order, but HRSA could still issue a negative audit finding The exit conference is the last opportunity to present additional evidence or influence the report that the auditor makes to HRSA
63 Lessons Learned The auditor will expect to see written policies and procedures, and will verify that they are actually followed HRSA has issued adverse findings in more than half of audits, though many relate to inaccurate database entries HRSA will respond to additional evidence submitted with the Notice of Disagreement, and legal assistance is preferable if possible
64 Lessons Learned Many areas of the 340B program are governed by informal guidance and OPA/Apexus frequently asked questions, and not all are legally enforceable In other words, even accurate findings might not require corrective action If you use an administrator, ensure that the vendor is prepared to assist you Auditors look for flaws they have found before stay abreast of recent findings
65 Lessons Learned Prior to the audit, responsible individuals should have defined roles. For example, one person might be in charge of retrieving patient records and another might be in charge of navigating pharmacy records
66 The Mega-Reg, Litigation, and Political Environment
67 The Mega-Reg In response to pressure from stakeholders, HRSA indicated it would convert some or all of its guidance into legally enforceable regulations Came to be known as the Mega-Reg Drug industry argues that the program has operated without proper oversight and that abuse is occurring Expected to establish updated patient definition, contract pharmacy guidelines, and cover other critical areas
68 HRSA s First 340B Regulation In August 2013, HRSA issued its first 340B regulation, addressing the circumstances in which certain hospital types could purchase drugs with an orphan designation PhRMA disapproved, and filed suit alleging that HRSA lacked the authority to issue regulations and that the regulation conflicted with the statute
69 Unintended Consequences A federal judge in the District of Columbia agreed that HRSA lacked the authority to issue regulations Only authorized to regulate in very narrow areas: dispute resolution process, establishment of civil monetary penalties when manufacturers overcharge So Mega-Reg that PhRMA wanted is now indefinitely on hold
70 Now What? HRSA could go to Congress and ask it to pass a law giving it the authority to regulate in other areas BUT Once Congress takes the lid off of 340B, what other tinkering might program critics do? HRSA could issue the mega-reg as more interpretive guidance BUT Program critics might have leverage to convince Congress that the whole program needs an overhaul
71 Political Climate & Calculus
72 Q&A
73 Jason Reddish Attorney - Powers Pyles Sutter & Verville PC 1501 M Street NW, 7 th Floor Washington, DC (202) Jason.Reddish@ppsv.com Contact Me
74 Stay on Fire! APHCA Training Schedule Request organizational training or assistance: Celeste Drayden
This training will begin at 12:00pm ET. WebEx Technical Support: Or us at
This training will begin at 12:00pm ET WebEx Technical Support: 1-866-229-3239 Or e-mail us at nationalhivcenter@fenwayhealth.org Works with HIV/AIDS service organizations and community-based organizations
More informationCOMPLIANCE IN THE 340B DRUG PRICING PROGRAM
COMPLIANCE IN THE 340B DRUG PRICING PROGRAM Jason Atlas RPh MBA Manager, Education and Compliance Support Apexus Education and Compliance Support Team Apexus Education and Compliance Support Team 1 Objectives
More information340B: WHAT ATTORNEYS NEED TO KNOW TODAY, TOMORROW AND IN THE FUTURE. March 3, 2016 ABA Emerging Issues in Healthcare Conference San Diego, CA
340B: WHAT ATTORNEYS NEED TO KNOW TODAY, TOMORROW AND IN THE FUTURE March 3, 2016 ABA Emerging Issues in Healthcare Conference San Diego, CA 2 Presentation Outline What you need to know Today 340B Program
More information340B Drug Pricing Program
340B Drug Pricing Program Mary Stepanyan, PharmD Candidate 2018 University of Southern California, School of Pharmacy Pro Pharma Pharmaceutical Consultants Under the preceptorship of Dr. Craig Stern WHY
More informationHow to Survive a HRSA Audit & Take Corrective Action. William von Oehsen, Principal Powers Pyles Sutter & Verville, PC
How to Survive a HRSA Audit & Take Corrective Action William von Oehsen, Principal Powers Pyles Sutter & Verville, PC Statement of Conflicts of Interest William von Oehsen represents 340B providers and
More informationMATERIAL COVERED TODAY
MATERIAL COVERED TODAY This presentation has been designed to discuss compliance needs, proposed changes and best practices for covered entities in the 340B Drug Pricing Program This presentation should
More informationTHE 340B DRUG DISCOUNT PROGRAM AND INTERPLAY WITH MEDICARE AND MEDICAID REIMBURSEMENT PRINCIPLES. Barbara Straub Williams.
THE 340B DRUG DISCOUNT PROGRAM AND INTERPLAY WITH MEDICARE AND MEDICAID REIMBURSEMENT PRINCIPLES I. History and Purpose of 340B Program Barbara Straub Williams March 2015 Section 340B of the Public Health
More informationRenee Gravalin, Partner
Experience the Eide Bailly Difference 340B Drug Program Renee Gravalin, Partner rgravalin@eidebailly.com 701.799.5449 Agenda Proposed Changes 1 Experience the Eide Bailly Difference Created in 1992 to
More informationIntroduction. The Basics of the 340B Program. 340B Drug Discount Program Compliance, Audit & Enforcement Activity. Wesley R.
340B Drug Discount Program Compliance, Audit & Enforcement Activity Wesley R. Butler Wes.Butler@BBB-Law.com Introduction Caveat This presentation is intended as an overview of a complex area of law and
More information6/11/2013. South Carolina Primary Health Care Association. Overview. 340B Essentials. Disclaimer. 340B Essentials. 340B Essentials
South Carolina Primary Health Care Association 2013 Clinical Network Retreat June 9, 2013 Preparing for and Surviving a 340B Audit presented by: Michael B. Glomb, Partner of Overview Key features of the
More informationWebinar Schedule. I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance
Webinar Schedule I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance II. Stakeholder Response to the 340B Ceiling Price and Manufacturer CMP Proposed Rule Thursday, Oct. 8, 2005
More informationWhat is the 340B Program?
Emily Cook, Partner, McDermott Will & Emery Anne S. Daly, Senior Director of Compliance, Banner Health Karolyn Woo Miles, Principal, Deloitte & Touche LLP 1 What is the 340B Program? Federal drug discount
More informationThe 340B Drug Pricing Program
The 340B Drug Pricing Program Presentation at Alliance of Community Health Plans Medical Directors and Pharmacy Directors Meeting October 2012 Avalere Health LLC Avalere Health LLC The intersection of
More information340B Program Update & Recommendations for Monitoring Program Compliance October
340B Program Update & Recommendations for Monitoring Program Compliance October 2 2014 Speaker Biography Ray Albertina Director Deloitte & Touche LLP +1 (314) 342 4984 ralbertina@deloitte.com Ray is a
More informationStructuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements
Presenting a live 90-minute webinar with interactive Q&A Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements WEDNESDAY, MARCH 19, 2014 1pm Eastern 12pm Central 11am
More informationThe 340B Program: Challenges and Opportunities
The 340B Program: Challenges and Opportunities March 2015 Thomas Barker Igor Gorlach Foley Hoag LLP Overview Overview and History of the 340B Program ACA s Changes to the 340B Program Recent Developments
More informationAn Introduction to and Updated Regarding the 340B Federal Drug Discount Program
An Introduction to and Updated Regarding the 340B Federal Drug Discount Program Chris Roberson, JD, MPH 317.871.0000 or 877.256.8837 Raphael Health Center Picture of CHC Describe how many centers and how
More information340B Drug Pricing: Don t Become an HRSA Statistic. Wipfli LLP 1
340B Drug Pricing: Don t Become an HRSA Statistic October 13, 2017 Wipfli LLP 1 Today s Agenda 340B Drug Pricing Program Overview Program Benefit Eligibility Program in Operation Contract Pharmacy Regulatory
More information340B Drug Program Compliance: Focus on Disproportionate Hospitals
340B Drug Program Compliance: Focus on Disproportionate Hospitals Part II: 340B Drug Program Compliance: Pharmacy Operations and the DSH January 29, 2014 1 Faculty Stephen J. Weiser, JD, LLM Director 312-403-4284
More informationTable of Contents. Executive Resources, LLC 2015, v. 2
2 Table of Contents I. Introduction II. Overview III. Contract Pharmacy and Arrangements IV. HRSA and 340B Data Base V. Software, Internal Control Systems and Management of Inventory VI. External Relationships
More informationAmerica s Voice for Community Health Care
America s Voice for Community Health Care The National Association of Community Health Centers (NACHC) represents Community and Migrant Health Centers, as well as Health Care for the Homeless and Public
More information340B Pharmacy Program Compliance insight. ideas Kentucky Primary Care Association attention
340B Pharmacy Program Compliance Kentucky Primary Care Association Presented by: Scott Gold, CPA, Partner October 16, 2012 Brief Overview History of 340B Drug Program Discounted Pharmaceuticals Growing
More information340B Program: Mega Guidance, Mega Change Pershing Yoakley & Associates, PC (PYA).
340B Program: Mega Guidance, Mega Change No portion of this white paper may be used or duplicated by any person or entity for any purpose without the express written permission of PYA. For many years,
More information1/16/2014. David Pointer President, SolutionsRx
David Pointer President, SolutionsRx 417.679.2203 david@pointerlaw.com 1 340B Program Overview Physician-Administered Drugs Contract Pharmacies 340B Compliance Expanding 340B Utilization 2 Federally mandated
More informationBKD NATIONAL HEALTH CARE GROUP
BKD NATIONAL HEALTH CARE GROUP PRESCRIPTION FOR 340B SUCCESS IN 2018 February 14, 2018 BRIAN BELL DIRECTOR BBELL@BKD.COM TO RECEIVE CPE CREDIT Participate in entire webinar Answer polls when they are provided
More information10/2/2015. CPAs and ADVISORS 340B: COMPLIANCE MATTERS AND HERE S WHY MICHAEL R. EARLS, CPA DIRECTOR. experience access // 2 // experience access
CPAs and ADVISORS experience access // 340B: COMPLIANCE MATTERS AND HERE S WHY MICHAEL R. EARLS, CPA DIRECTOR MATERIALS COVERED TODAY 340B Program Evolution, Purpose & Benefits HRSA & Manufacturer Audits
More informationFollowing this presentation, attendees should be able to: Identify key events in 340B landscape that occurred in 2015 and 2016.
Following this presentation, attendees should be able to: Identify key events in 340B landscape that occurred in 2015 and 2016. Identify critical components of a compliance plan. List the different types
More information2/25/2016. Today s Objectives. Disclaimer WHAT S NEW IN THE WORLD OF 340B?
WHAT S NEW IN THE WORLD OF 340B? Jim Donnelly Vice President of Pharmacy Services Hudson Headwaters Health Network Jennifer Bolster Partner Hancock Estabrook, LLP. Friday, February 26 th Today s Objectives
More informationA Pharmacy s Guide to 340B Contract Pharmacy Services Best Practices
A Pharmacy s Guide to 340B Contract Pharmacy Services Best Prepared by: Date: September 1, 2014 Table of Contents Overview... 1 Introduction to the 340B program... 3 340B Covered Entity Eligibility...
More informationThe 340B Drug Pricing Program: Opportunities for Community Pharmacists
The 340B Drug Pricing Program: Opportunities for Community Pharmacists by Marsha K. Millonig, MBA, RPh President,Catalyst Enterprises, LLC Goals: After completing this program, participants will be able
More informationExclusion of Orphan Drugs for Certain Covered Entities under 340B Program
Billing Code: 4165-15 DEPARTMENT OF HEALTH AND HUMAN SERVICES 42 CFR Part 10 RIN 0906- AA94 Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program AGENCY: Health Resources and Services
More informationSteve Zielinski Regional Director SUNRx, LLC April 16, 2010
Steve Zielinski Regional Director SUNRx, LLC April 16, 2010 Mississippi Primary Care Association 340B Program Overview Contracted Pharmacy Model New Multiple Contract Pharmacy Elements Maintaining 340B
More information340B MEGA GUIDANCE WHAT NOW? KENTUCKY HFMA WINTER INSTITUTE JANUARY 21, 2016
340B MEGA GUIDANCE WHAT NOW? KENTUCKY HFMA WINTER INSTITUTE JANUARY 21, 2016 Brian Bell Director bbell@bkd.com Brenda Christman Managing Director bchristman@bkd.com MATERIAL COVERED TODAY The Health Resources
More informationStatement of Conflicts of Interest
Part 1 - Overview Debra A. Muscio, MBA, CHC, CCE, CFE SVP, Chief Audit, Ethics & Officer Community Medical Centers Karolyn Woo-Miles Senior Manager Deloitte & Touche LLP April 22, 2015 Statement of Conflicts
More information340B Program New Developments and Increasing Scrutiny
340B Program New Developments and Increasing Scrutiny Todd Nova Hall Render tnova@hallrender.com Wisconsin Office of Rural Health Hospital Finance Workshop August 24, 2012 What We Will Cover 2 1 340B Program
More information340B Contract Pharmacy Arrangements: What Does the Future Hold?
Presenting a live 90-minute webinar with interactive Q&A 340B Contract Pharmacy Arrangements: What Does the Future Hold? Structuring Arrangements, Meeting Legal and Regulatory Requirements THURSDAY, DECEMBER
More information340B Compliance, Audits & Opportunities
340B Compliance, Audits & Opportunities NW Ohio HFMA February 15, 2018 David Layne, CPA Manager HRSA Audits Bizzell Group-Silver Spring, Maryland Prior Hospital experience Many are pharmacists Experienced
More information340B Program Contract Pharmacy Self-Audit Tool: Diversion
Page 1 Purpose: The purpose of the Contract Pharmacy Self-Audit Tools is to improve contract pharmacies compliance with the 340B Program requirements. Covered entities remain responsible for the 340B drugs
More informationContract Pharmacy Relationships
Contract Pharmacy Relationships What is a contract pharmacy? 1 What is a contract pharmacy? Dispenses drugs to FQHC patients on behalf of FQHC Contract between FQHC and pharmacy Typically pharmacy not
More information340B MEGA GUIDANCE WHAT NOW? HFMA REGION 6 DECEMBER 16, 2015
340B MEGA GUIDANCE WHAT NOW? HFMA REGION 6 DECEMBER 16, 2015 Brian Bell Director bbell@bkd.com Claire Torrella Manager ctorrella@bkd.com MATERIAL COVERED TODAY The Health Resources and Services Administration
More information340B Pharmacy Program Best Practices
340B Pharmacy Program Best Practices December 8, 2015 Agenda 1. The Program and the Requirements 2. Program Compliance and Integrity (Best Practices) Internal Controls Policies and Procedures OPA Database
More information340B Compliance: Overcoming Challenges with Diversion, Duplicate Discounts, and Orphan Drug Restrictions
Presenting a live 90-minute webinar with interactive Q&A 340B Compliance: Overcoming Challenges with Diversion, Duplicate Discounts, and Orphan Drug Restrictions WEDNESDAY, JANUARY 15, 2014 1pm Eastern
More informationFPNTC FAMILY PLANNING NATIONAL TRAINING CENTER
Demystifying 340B: Frequently Asked Questions Webinar February 13, 2018 FPNTC Responses to Unanswered Chat Questions Mindy McGrath, National Family Planning and Reproductive Health Association (NFPRHA)
More informationThe 340B drug discount program was created in 1992
Proposed Rule Changes for 340B Programs: Overview and Impact Anthony Zappa, PharmD, MBA Specialty Healthcare Benefits Council The 340B drug discount program was created in 1992 as a means for certain nonprofit
More information11/5/2015 A&A PERSPECTIVE. HFMA Region 9 Conference November 15, Tracy Young, CPA, Partner Brian Bell, Director
340B MEGA GUIDANCE FROM AN A&A PERSPECTIVE HFMA Region 9 Conference November 15, 2015 Tracy Young, CPA, Partner Brian Bell, Director 1 MATERIAL COVERED TODAY The Health Resources and Services Administration
More information340B Drug Pricing Program: Participation, Eligibility and Program Integrity HOSPITALS June 26 th, 2014
340B Drug Pricing Program: Participation, Eligibility and Program Integrity HOSPITALS June 26 th, 2014 LCDR Joshua E. Hardin MBA, RN/BSN, MLT U.S. Department of Health and Human Services Health Resources
More informationNEGATIVE CONSEQUENCES OF THE OHIO PRESCRIPTION DRUG (or Rx) BALLOT ISSUE Families & Children in Medicaid, Pharmacy Services Are Impacted
NEGATIVE CONSEQUENCES OF THE OHIO PRESCRIPTION DRUG (or Rx) BALLOT ISSUE Families & Children in Medicaid, Pharmacy Services Are Impacted April 11, 2017 John McCarthy CEO, Upshur Street Consulting LLC,
More informationHealth Reform Update: Focus on Prescription Drug Price Regulation
International Life Sciences Arbitration Health Industry Alert If you have questions or would like additional information on the material covered in this Alert, please contact the author: Joseph W. Metro
More informationRyan White & the Affordable Care Act: Frequently Asked Questions
1 of 10 9/13/2013 4:23 PM HIV/AIDS Programs Home Ryan White & the Affordable Care Act: Frequently Asked Questions Share 0 Here you will find answers to frequently asked questions about the Ryan White Program
More informationCompliance Risk Areas for Health Centers: A Financial Perspective. Marcie H. Zakheim Partner
Compliance Risk Areas for Health Centers: A Financial Perspective Marcie H. Zakheim Partner DISCLAIMER This training has been prepared by the attorneys of Feldesman Tucker Leifer Fidell LLP. The opinions
More informationPharmaceutical Summit on Business and Compliance Issues in Managed Markets
Pharmaceutical Summit on Business and Compliance Issues in Managed Markets TRACK A: 340B PROGRAM CONSIDERATIONS A Panel Discussion By: Agenda Panel Introductions Overview of 340B Program Compliance Considerations
More information340B Program Risk: A Perspective for Pharmaceutical Manufacturers
CiiTA Monograph Series 340B Program Risk: A Perspective for Pharmaceutical Manufacturers EXECUTIVE SUMMARY The number of ineligible prescriptions purchased through the PHS 340B Drug Discount Program represents
More information340B Drug Discount Program: Expansion Issues, Diversion Concerns, and Implications for Price Reporting and Compliance
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. 340B Drug Discount Program: Expansion Issues,
More informationChapter 9 Medicaid and 340B
Chapter 9 Medicaid and 340B A. Introduction UPDATED 1. The complex intersection of Medicaid and 340B The intersection of 340B and Medicaid is one of the most complex and significant areas within any health
More information340B Guardian Model Overview
340B Guardian Model Overview Why monitor 340B program compliance? The 340B program has grown from less than $2B in total sales in 2002 to over $8B in sales in 2012. Currently, approximately 30,000 covered
More informationRE: Proposed Rule: RIN 0906-AA90, 340B Drug Pricing Program; Administrative Dispute Resolution, (Vol. 81, No. 156, August 12, 2016)
Krista Pedley, Pharm.D, MS Captain, USPHS Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane, Mail Stop 08W05A Rockville, MD 20857 RE: Proposed Rule: RIN
More informationATTN: Comments on 340B Drug Pricing Program Omnibus Guidance
October 27, 2015 Krista Pedley Director, Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Rockville, MD 20857 ATTN: Comments on 340B Drug Pricing Program Omnibus
More informationHealth Policy Explainer
The 340B Drug Program Health Policy Explainer Created in 1992, the 340B Drug Discount Program is a little-known program that s getting an increasing amount of attention from hospitals, Congress and pharmaceutical
More informationA Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part II
April 2017 Follow @Paul_Hastings A Special Type of Government Scrutiny: Pharmaceutical Manufacturer Relationships with Specialty Pharmacies: Part II By Gary F. Giampetruzzi & Jonathan Stevens Reproduced
More informationCommitment to Compliance
Introduction Commitment to Compliance SelectHealth has a compliance oversight program which supports compliant behavior by its employees and any of its contracted business partners, including first -tier,
More informationAugust 11, Submitted electronically via Regulations.gov
August 11, 2017 Submitted electronically via Regulations.gov Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1678-P PO Box 8013 Baltimore, MD 21244-1850
More informationMEDICAID AND BUDGET RECONCILIATION: IMPLICATIONS OF THE CONFERENCE REPORT
Updated January 2006 MEDICAID AND BUDGET RECONCILIATION: IMPLICATIONS OF THE CONFERENCE REPORT In compliance with the budget resolution that passed in April 2005, the House and Senate both passed budget
More informationRx Office Hours: IMPORTANT
Rx Office Hours: IMPORTANT To ensure a high quality audio experience for all, please: Dial in using your phone (NOT your computer.) Enter your personal Attendee ID (located in the left hand box, below
More informationHRSA Publishes 340B Drug Pricing Program Omnibus Guidance Notice: Significant Policy Ramifications Should Trigger Public Comment
Alert Life Sciences Health Industry If you have questions or would like additional information on the material covered in this Alert, please contact one of the attorneys listed below: Joseph W. Metro Partner,
More informationDEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS
DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All MASSACHUSETTS WORKFORCE MEMBERS The Company is committed to preventing health care fraud, waste and abuse and complying with applicable
More informationDEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS
DEFICIT REDUCTION ACT AND FALSE CLAIMS POLICY INFORMATION FOR All NEW YORK WORKFORCE MEMBERS The Company is committed to preventing health care fraud, waste and abuse and complying with applicable state
More informationThe Future of 340B. Disclosure
1 The Future of 340B NCPA 2018 Annual Convention Susan Pilch, JD, Senior Vice President, Legal and Advocacy, 340B Health Amanda Gaddy, RPh, Co Founder, Secure340B Disclosure Susan Pilch declares no conflicts
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of Inspector General s Use of Agreements to Protect the Integrity of Federal Health Care Programs
United States Government Accountability Office Report to Congressional Requesters April 2018 DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of Inspector General s Use of Agreements to Protect the Integrity
More informationTX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement
January 31, 2014 VIA ELECTRONIC SUBMISSION Vendor Drug Program Medicaid/CHIP Division 4900 N. Lamar Austin, Texas 78751 RE: TX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement
More information8 th Annual Oncology Economics Summit Estimating the Impact of Recent Legislation on Future Growth in the 340B Program
8 th Annual Oncology Economics Summit Estimating the Impact of Recent Legislation on Future Growth in the 340B Program La Jolla, CA February 21-22, 2012 1 Legal Made Me Do It The opinions expressed in
More informationUnderstanding and Effectively Negotiating Contracts
Understanding and Effectively Negotiating Contracts Stephen K. Phillips Principal Hooper, Lundy & Bookman, P.C. 1 Los Angeles San Francisco San Diego Washington D.C. What is a Contract? An enforceable
More informationFraud, Waste and Abuse: Compliance Program. Section 4: National Provider Network Handbook
Fraud, Waste and Abuse: Compliance Program Section 4: National Provider Network Handbook December 2015 2 Our Philosophy Magellan takes provider fraud, waste and abuse We engage in considerable efforts
More informationDecember 1, Maryland Department of Health and Mental Hygiene. Prepared by:
Report in Response to Legislative Request to the Maryland Department of Health and Mental Hygiene to Study the Feasibility of Purchasing Prescription Drugs through Federally Qualified Health Centers and
More informationGERALD (JERRY) LEWANDOWSKI. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036
Curriculum Vitae GERALD (JERRY) LEWANDOWSKI BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, Second Floor Washington, DC 20036 Direct: 202.480.2643 Mobile: 202.258.2669 jlewandowski@thinkbrg.com Jerry Lewandowski
More informationA DISCUSSION WITH THE OIG
1 A DISCUSSION WITH THE OIG MICHAEL J ARMSTRONG REGIONAL INSPECTOR GENERAL FOR AUDIT SERVICES STEPHEN J CONWAY DIRECTOR, ADVANCED AUDIT TECHNIQUES ROBERT K DECONTI CHIEF, ADMINISTRATIVE & CIVIL REMEDIES
More informationOklahoma Health Care Authority
Oklahoma Health Care Authority It is very important that you provide your comments regarding the proposed rule change by the comment due date. Comments are directed to Oklahoma Health Care Authority (OHCA)
More informationAccessCUBICIN Enrollment Form
Services Requested REQUIRED Choose the Services that are being Requested INSTRUCTIONS FOR COMPLETING THIS FORM Patient Information REQUIRED Include the primary contact; if other than the patient, include
More informationESSENTIAL COMMUNITY PROVIDER PETITION FOR 2017 BENEFIT YEAR FREQUENTLY ASKED QUESTIONS
/Dean M. Seyler/ ESSENTIAL COMMUNITY PROVIDER PETITION FOR 2017 BENEFIT YEAR FREQUENTLY ASKED QUESTIONS Q1. Under what authority is HHS collecting this provider data? A1. In accordance with section 1311(c)(1)(C)
More informationCRS Report for Congress Received through the CRS Web
CRS Report for Congress Received through the CRS Web Order Code RS20295 August 9, 1999 Outpatient Prescription Drugs: Acquisition and Reimbursement Policies Under Selected Federal Programs Heidi G. Yacker
More informationHealth Insurance and HIV
Health Insurance and HIV Use this guide to find out how you can get help paying for your HIV care and other health needs, including the answers to these questions: Why do I need health insurance? How can
More informationDEFICIT REDUCTION ACT OF 2005: IMPLICATIONS FOR MEDICAID PREMIUMS AND COST SHARING CHANGES
February 2006 DEFICIT REDUCTION ACT OF 2005: IMPLICATIONS FOR MEDICAID On February 8, 2006 the President signed the Deficit Reduction Act of 2005 (DRA). The Act is expected to generate $39 billion in federal
More informationHIV/AIDS Bureau, Division of Service Systems Monitoring Standards for Ryan White Part A and B Grantees: Part A Fiscal Monitoring Standards
HIV/AIDS Bureau, Division of Service Systems Monitoring s for Ryan White Part A and B Grantees: Part A Fiscal Monitoring s Table of Contents Section A: Limitation on Uses of Part A funding Section B: Unallowable
More informationPLEASE CHECK ALL BOXES THAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM
The Merck Access Program 2019 ENROLLMENT FORM Phone: 855-257-3932, Fax: 855-755-0518 The Merck Access Program, PO Box 29067, Phoenix, AZ 85038 TO GET STARTED, COMPLETE THE ENROLLMENT FORM AND FAX IT TO
More informationContracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016
Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress October 20, 2016 Thomas Beimers Hogan Lovells Thomas.beimers@hoganlovells.com Sarah Franklin Covington
More informationIssue brief: Medicaid managed care final rule
Issue brief: Medicaid managed care final rule Overview In the past decade, the Medicaid managed care landscape has changed considerably in terms of the number of beneficiaries enrolled in managed care
More informationHIPAA AND LANGUAGE SERVICES IN HEALTH CARE 1
1101 14th St NW, Suite 405 Washington, DC 20005 (202) 289-7661 Fax (202) 289-7724 HIPAA AND LANGUAGE SERVICES IN HEALTH CARE 1 In 1996, the Health Insurance Portability and Accountability Act (HIPAA) became
More informationGrayson and Associates, P. C.
Grayson and Associates, P. C. PATIENT INFORMATION Patient Name Date of Birth Social Security Number - - Male Female Mailing Address City State Zip Email Is it ok for Grayson and Associates, P.C. to communicate
More informationStark Self-Disclosure. Thomas S. Crane 1/ Mintz Levin Cohn Ferris Glovsky and Popeo, PC
Stark Self-Disclosure Thomas S. Crane 1/ Mintz Levin Cohn Ferris Glovsky and Popeo, PC A. Background 1. Stark Law The Physician Self-Referral Statute (or the Stark Law ) prohibits a physician from referring
More informationSelf-Disclosure: Why, When, Where and How
American Bar Association Washington Health Law Summit Self-Disclosure: Why, When, Where and How December 8, 2015 Margaret Hutchinson U.S. Attorney s Office for the Eastern District of Pennsylvania Kaitlyn
More informationStructuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII
Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment Mini Summit XVIII The 16 th Pharmaceutical Compliance Congress and Best Practices Forum Thursday, October
More information340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties. AGENCY: Health Resources and Services Administration, HHS.
This document is scheduled to be published in the Federal Register on 06/05/2018 and available online at https://federalregister.gov/d/2018-12103, and on FDsys.gov Billing Code: 4165-15 DEPARTMENT OF HEALTH
More informationHIV/AIDS Bureau, Division of Metropolitan HIV/AIDS Programs National Monitoring Standards for Ryan White Part A Grantees: Fiscal Part A
HIV/AIDS Bureau, Division of Metropolitan HIV/AIDS Programs National Monitoring Standards for Ryan White Part A Grantees: Fiscal Part A Table of Contents Section A: Limitation on Uses of Part A funding
More informationAmgen GLOBAL CORPORATE COMPLIANCE POLICY
1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees and temporary staff worldwide ( Covered Persons ). Consultants, contract
More informationCOMPARING VERAGE SALES PRICES AND AVERAGE MANUFACTURER PRICES FOR MEDICARE PART B DRUGS: AN OVERVIEW OF 2013
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL A COMPARING VERAGE SALES PRICES AND AVERAGE MANUFACTURER PRICES FOR MEDICARE PART B DRUGS: AN OVERVIEW OF 2013 Suzanne Murrin Deputy
More informationAlabama s Ryan White Part B Program Eligibility Standard
PURPOSE This document establishes guidelines to determine eligibility of persons seeking services through Ryan White Part B and the State s AIDS Drug Assistance Program (ADAP). This policy is binding to
More informationPLEASE CHECK ALL BOXES THAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM. Patient name: _Date of birth: Sex: M F
The Merck Access Program ENROLLMENT FORM Phone: 855-257-3932, Fax: 855-755-0518, TTY: 855-257-7332 The Merck Access Program, PO Box 29067, Phoenix, AZ 85038 TO GET STARTED, COMPLETE THE ENROLLMENT FORM
More informationMedicaid Prescribed Drug Program Spending Control Initiatives. For the Quarter April 1, 2014 through June 30, 2014
Medicaid Prescribed Drug Program Spending Control Initiatives For the Quarter April 1, 2014 through June 30, 2014 Report to the Florida Legislature January 2015 Table of Contents Purpose of Report... 1
More informationManufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
More informationANTI-FRAUD PLAN INTRODUCTION
ANTI-FRAUD PLAN INTRODUCTION We recognize the importance of preventing, detecting and investigating fraud, abuse and waste, and are committed to protecting and preserving the integrity and availability
More informationBraeburn Patient Assistance Program Application
The provides Probuphine at no cost to patients that do not have healthcare coverage and/or adequate coverage for Probuphine. All applications are reviewed on a case-by-case basis to support the Braeburn
More information